Bio-Path Holdings (BPTH) has a debt-to-equity ratio of -0.05, below the Healthcare sector average of 0.31.
Get informed when a big investor buys or sells
+ Follow-0.05
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
Bio-Path Holdings (BPTH) currently reports a debt-to-equity ratio of -0.05. That is below the Healthcare sector average of 0.31. Use the charts on this page to explore Bio-Path Holdings's debt-to-equity ratio history and peer comparisons.
Bio-Path Holdings's debt-to-equity ratio of -0.05 is lower than the Healthcare sector average of 0.31. That is roughly 117.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The debt-to-equity ratio is a valuation multiple that relates Bio-Path Holdings's market price to a fundamental measure such as earnings, sales, or book value. At -0.05, BPTH can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current debt-to-equity ratio of -0.05, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.31. From there, open related valuation or income-statement pages for Bio-Path Holdings, and consider following BPTH for alerts when major investors trade the stock.
Bio-Path Holdings is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows -0.05 versus a sector average near 0.31. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BPTH with unrelated industries.